Cargando…
Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease
BACKGROUND: Growing body of evidence suggests that Parkinson’s disease (PD) is associated with oxidative damage via iron accumulation in the substantia nigra (SN). Low ceruloplasmin (CP)-ferroxidase activity has been identified in the SN and the cerebrospinal fluid (CSF) of patients with PD. The iro...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429376/ https://www.ncbi.nlm.nih.gov/pubmed/25943368 http://dx.doi.org/10.1186/s12883-015-0331-3 |
_version_ | 1782371024817356800 |
---|---|
author | Grolez, Guillaume Moreau, Caroline Sablonnière, Bernard Garçon, Guillaume Devedjian, Jean-Christophe Meguig, Sayah Gelé, Patrick Delmaire, Christine Bordet, Regis Defebvre, Luc Cabantchik, Ioav Z Devos, David |
author_facet | Grolez, Guillaume Moreau, Caroline Sablonnière, Bernard Garçon, Guillaume Devedjian, Jean-Christophe Meguig, Sayah Gelé, Patrick Delmaire, Christine Bordet, Regis Defebvre, Luc Cabantchik, Ioav Z Devos, David |
author_sort | Grolez, Guillaume |
collection | PubMed |
description | BACKGROUND: Growing body of evidence suggests that Parkinson’s disease (PD) is associated with oxidative damage via iron accumulation in the substantia nigra (SN). Low ceruloplasmin (CP)-ferroxidase activity has been identified in the SN and the cerebrospinal fluid (CSF) of patients with PD. The iron chelator, deferiprone, reduces the abnormally high levels of iron in the SN. In order to determine CP’s involvement in iron accumulation in SN and PD progression, we aim to compare the ability of iron chelation treatment to reducing both SN iron levels and motor handicap in PD patients according to the level of ceruloplasmin activity. METHODS: We used a moderate chelation protocol with deferiprone (DFP) based on a, 6-month delayed-start paradigm, randomized placebo controlled clinical trial in 40 PD patients. CP-ferroxidase activity was determined in blood and CSF together with the D544E gene polymorphism (rs701753). Iron levels were determined by R2* MRI sequence and the motor handicap by the UPDRS motor score. RESULTS: After 6 to 12 months of DFP treatment, greater reductions in SN iron levels and UPDRS motor scores were obtained in patients with higher serum and CSF levels of CP-ferroxidase activity. After 6 months of DFP treatment, the AT genotype group displayed greater reduction of iron level in the SN with greater CSF and serum levels of CP activity than the AA genotype group. CONCLUSION: Although most of the DFP-treated patients displayed clinical and radiological improvements, those with the lower CP activity appeared to respond better to iron chelation. Larger RCTs are now needed to establish whether pharmacological modulation of CP activity could be an innovative neuroprotective strategy in PD. TRIAL REGISTRATION: FAIR-PARK study (ClinicalTrials.gov reference: NCT00943748; French national reference number: 2008−006842−25). This study was approved by the French Drug Agency (ANSM) and the local institutional review board (“Comité de Protection des Personnes of Lille”). ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12883-015-0331-3) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4429376 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-44293762015-05-14 Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease Grolez, Guillaume Moreau, Caroline Sablonnière, Bernard Garçon, Guillaume Devedjian, Jean-Christophe Meguig, Sayah Gelé, Patrick Delmaire, Christine Bordet, Regis Defebvre, Luc Cabantchik, Ioav Z Devos, David BMC Neurol Research Article BACKGROUND: Growing body of evidence suggests that Parkinson’s disease (PD) is associated with oxidative damage via iron accumulation in the substantia nigra (SN). Low ceruloplasmin (CP)-ferroxidase activity has been identified in the SN and the cerebrospinal fluid (CSF) of patients with PD. The iron chelator, deferiprone, reduces the abnormally high levels of iron in the SN. In order to determine CP’s involvement in iron accumulation in SN and PD progression, we aim to compare the ability of iron chelation treatment to reducing both SN iron levels and motor handicap in PD patients according to the level of ceruloplasmin activity. METHODS: We used a moderate chelation protocol with deferiprone (DFP) based on a, 6-month delayed-start paradigm, randomized placebo controlled clinical trial in 40 PD patients. CP-ferroxidase activity was determined in blood and CSF together with the D544E gene polymorphism (rs701753). Iron levels were determined by R2* MRI sequence and the motor handicap by the UPDRS motor score. RESULTS: After 6 to 12 months of DFP treatment, greater reductions in SN iron levels and UPDRS motor scores were obtained in patients with higher serum and CSF levels of CP-ferroxidase activity. After 6 months of DFP treatment, the AT genotype group displayed greater reduction of iron level in the SN with greater CSF and serum levels of CP activity than the AA genotype group. CONCLUSION: Although most of the DFP-treated patients displayed clinical and radiological improvements, those with the lower CP activity appeared to respond better to iron chelation. Larger RCTs are now needed to establish whether pharmacological modulation of CP activity could be an innovative neuroprotective strategy in PD. TRIAL REGISTRATION: FAIR-PARK study (ClinicalTrials.gov reference: NCT00943748; French national reference number: 2008−006842−25). This study was approved by the French Drug Agency (ANSM) and the local institutional review board (“Comité de Protection des Personnes of Lille”). ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12883-015-0331-3) contains supplementary material, which is available to authorized users. BioMed Central 2015-05-06 /pmc/articles/PMC4429376/ /pubmed/25943368 http://dx.doi.org/10.1186/s12883-015-0331-3 Text en © Grolez et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Grolez, Guillaume Moreau, Caroline Sablonnière, Bernard Garçon, Guillaume Devedjian, Jean-Christophe Meguig, Sayah Gelé, Patrick Delmaire, Christine Bordet, Regis Defebvre, Luc Cabantchik, Ioav Z Devos, David Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease |
title | Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease |
title_full | Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease |
title_fullStr | Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease |
title_full_unstemmed | Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease |
title_short | Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease |
title_sort | ceruloplasmin activity and iron chelation treatment of patients with parkinson’s disease |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429376/ https://www.ncbi.nlm.nih.gov/pubmed/25943368 http://dx.doi.org/10.1186/s12883-015-0331-3 |
work_keys_str_mv | AT grolezguillaume ceruloplasminactivityandironchelationtreatmentofpatientswithparkinsonsdisease AT moreaucaroline ceruloplasminactivityandironchelationtreatmentofpatientswithparkinsonsdisease AT sablonnierebernard ceruloplasminactivityandironchelationtreatmentofpatientswithparkinsonsdisease AT garconguillaume ceruloplasminactivityandironchelationtreatmentofpatientswithparkinsonsdisease AT devedjianjeanchristophe ceruloplasminactivityandironchelationtreatmentofpatientswithparkinsonsdisease AT meguigsayah ceruloplasminactivityandironchelationtreatmentofpatientswithparkinsonsdisease AT gelepatrick ceruloplasminactivityandironchelationtreatmentofpatientswithparkinsonsdisease AT delmairechristine ceruloplasminactivityandironchelationtreatmentofpatientswithparkinsonsdisease AT bordetregis ceruloplasminactivityandironchelationtreatmentofpatientswithparkinsonsdisease AT defebvreluc ceruloplasminactivityandironchelationtreatmentofpatientswithparkinsonsdisease AT cabantchikioavz ceruloplasminactivityandironchelationtreatmentofpatientswithparkinsonsdisease AT devosdavid ceruloplasminactivityandironchelationtreatmentofpatientswithparkinsonsdisease |